Skip to main content
Journal cover image

Initial testing of cisplatin by the pediatric preclinical testing program.

Publication ,  Journal Article
Tajbakhsh, M; Houghton, PJ; Morton, CL; Kolb, EA; Gorlick, R; Maris, JM; Keir, ST; Wu, J; Reynolds, CP; Smith, MA; Lock, RB
Published in: Pediatr Blood Cancer
May 2008

BACKGROUND: Cisplatin is one of the most widely used drugs for the treatment of solid tumors in adults and children. Here, we report the activity of cisplatin against the PPTP panels of childhood cancer xenografts. PROCEDURES: Cisplatin was evaluated against 23 cell lines, and 40 xenografts representing brain tumors, neuroblastoma, rhabdoid tumors, sarcoma, Wilms tumor, and acute lymphoblastic leukemia (ALL). The IC(50) concentration in vitro was determined for 96 hr exposure. Solid tumors were grown subcutaneously in immune-deficient mice, and tumor dimensions measured weekly. ALL xenografts were inoculated intravenously and the percent human CD45(+) cells in the peripheral blood determined weekly. The antitumor activity of cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21) was evaluated using time to event (EFS T/C), tumor growth delay (tumor volume T/C), and objective response measures. RESULTS: The median IC(50) concentration in vitro was 0.87 microM (0.24-4.29 microM), and cisplatin exhibited broad range activity. Cisplatin induced significant differences in EFS distributions compared to controls in 20/28 solid tumors and 4/8 ALL models. Objective responses were observed in 7/28 solid tumor models (25%): partial responses in three rhabdomyosarcomas and one Ewing's sarcoma; complete responses in one rhabdoid tumor and the medulloblastoma; and a maintained complete response in one Wilms tumor. No objective responses were observed in the ALL panel. CONCLUSIONS: Cisplatin exhibits significant antitumor activity against a broad range of solid tumor xenograft models and limited activity against ALL xenografts. This preclinical pattern of activity is generally consistent with cisplatin's clinical activity.

Duke Scholars

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

May 2008

Volume

50

Issue

5

Start / End Page

992 / 1000

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Wilms Tumor
  • Sarcoma
  • Rhabdomyosarcoma
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Neuroblastoma
  • Neoplasms
  • Mice, SCID
  • Mice, Inbred BALB C
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tajbakhsh, M., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Maris, J. M., … Lock, R. B. (2008). Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer, 50(5), 992–1000. https://doi.org/10.1002/pbc.21263
Tajbakhsh, Mimi, Peter J. Houghton, Christopher L. Morton, E Anders Kolb, Richard Gorlick, John M. Maris, Stephen T. Keir, et al. “Initial testing of cisplatin by the pediatric preclinical testing program.Pediatr Blood Cancer 50, no. 5 (May 2008): 992–1000. https://doi.org/10.1002/pbc.21263.
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, et al. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 May;50(5):992–1000.
Tajbakhsh, Mimi, et al. “Initial testing of cisplatin by the pediatric preclinical testing program.Pediatr Blood Cancer, vol. 50, no. 5, May 2008, pp. 992–1000. Pubmed, doi:10.1002/pbc.21263.
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 May;50(5):992–1000.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

May 2008

Volume

50

Issue

5

Start / End Page

992 / 1000

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Wilms Tumor
  • Sarcoma
  • Rhabdomyosarcoma
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Oncology & Carcinogenesis
  • Neuroblastoma
  • Neoplasms
  • Mice, SCID
  • Mice, Inbred BALB C